Cardiology
CHA₂DS₂-VASc Score
Stroke risk in atrial fibrillation, guiding anticoagulation.
Education and reference only. Not a substitute for clinical judgement, local policy or product labelling. Always verify before clinical use. Values are calculated in your browser and never stored.
Background
CHA₂DS₂-VASc estimates the annual risk of stroke and systemic embolism in people with non-valvular atrial fibrillation (AF), and is used to decide who should be offered anticoagulation. It refined the older CHADS₂ score by adding vascular disease, the 65–74 age band and female sex, which improved identification of genuinely low-risk people who do not need anticoagulation. Points are: Congestive heart failure or left-ventricular dysfunction (1), Hypertension (1), Age ≥75 (2), Diabetes (1), prior Stroke/TIA/thromboembolism (2), Vascular disease (1), Age 65–74 (1) and female Sex category (1) — a maximum of 9.
Interpreting the result
Risk rises continuously with the score, from roughly 0.2% per year at 0 to well above 10% per year at the highest scores. In practice: a man scoring 0 or a woman scoring 1 (from the sex point alone) is low risk and anticoagulation is generally not offered; a man scoring 1 warrants individual consideration; and most guidelines recommend anticoagulation once the score is ≥2 in men or ≥3 in women, absent contraindication. The score guides the decision but does not, by itself, choose the agent.
Advice
Guidelines generally suggest anticoagulation should be considered at a score of ≥2 in men and ≥3 in women, and may be considered at ≥1 in men / ≥2 in women. Decisions are individualised and shared.
Worked example
A 78-year-old woman with hypertension and type 2 diabetes: Age ≥75 (2) + Hypertension (1) + Diabetes (1) + female sex (1) = 5. This is a high annual stroke risk, so anticoagulation is recommended unless there is a strong contraindication — after also assessing and addressing her bleeding risk.
Critical actions
Always assess bleeding risk (e.g. HAS-BLED) and modifiable bleeding factors before starting anticoagulation. Score alone does not dictate therapy.
Pearls / pitfalls
- Female sex is a risk modifier, not a stand-alone indication: a woman whose only point is sex (score 1) is treated as low risk.
- Always pair it with a bleeding-risk assessment (e.g. HAS-BLED) and actively correct modifiable bleeding factors — a high bleeding score is a reason to manage risk, not to withhold anticoagulation reflexively.
- "Non-valvular" is key: mechanical heart valves or moderate-to-severe mitral stenosis need anticoagulation regardless of CHA₂DS₂-VASc.
- The score informs a shared decision; it does not replace clinical judgement or patient preference.
Evidence & validation
Derived and validated in large AF cohorts (Lip et al., based on the Euro Heart Survey) and adopted by major guidelines including ESC, NICE and AHA/ACC/HRS, which recommend it as the preferred stroke-risk tool in non-valvular AF.
Frequently asked questions
What CHA₂DS₂-VASc score is considered high?
Risk is continuous, but anticoagulation is generally recommended at ≥2 in men and ≥3 in women. A score of 0 in men (or 1 in women from the sex point alone) is low risk.
Does being female on its own mean a woman needs anticoagulation?
No. Female sex adds a point but is treated as a risk modifier — a woman whose only point comes from sex is regarded as low risk and is not routinely anticoagulated.
How is it different from CHADS₂?
CHA₂DS₂-VASc adds vascular disease, the 65–74 age band and female sex. It is better at identifying truly low-risk people who can safely avoid anticoagulation.
Does CHA₂DS₂-VASc tell me the bleeding risk?
No — it only estimates stroke/thromboembolism risk. Bleeding risk is assessed separately (for example with HAS-BLED).
Can I use it in valvular AF?
No. People with mechanical valves or moderate-to-severe mitral stenosis need anticoagulation irrespective of the score.
References
- Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach (CHA₂DS₂-VASc). Chest. 2010;137(2):263–272.
- Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021.
- NICE NG196: Atrial fibrillation: diagnosis and management. 2021.
About the creator
Prof. Gregory Y.H. Lip
Related calculators
Need a calculator we don't have — or a custom tool?
We build evidence-led clinical calculators, dashboards and reference tools for teams.